下调和上调
PI3K/AKT/mTOR通路
β氧化
内科学
内分泌学
心肌病
医学
过氧化物酶体增殖物激活受体
化学
作者
Yubi Lin,Ruonan Liu,Yanling Huang,Zhe Yang,Jianzhong Xian,Jingmin Huang,Zirui Qiu,Xiufang Lin,Mengzhen Zhang,Hui Chen,Huadong Wang,Jiana Huang,Geyang Xu
标识
DOI:10.1016/j.apsb.2022.05.018
摘要
Arrhythmogenic cardiomyopathy (ACM), a fatal heart disease characterized by fibroadipocytic replacement of cardiac myocytes, accounts for 20% of sudden cardiac death and lacks effective treatment. It is often caused by mutations in desmosome proteins, with Desmoglein-2 (DSG2) mutations as a common etiology. However, the mechanism underlying the accumulation of fibrofatty in ACM remains unknown, which impedes the development of curative treatment. Here we investigated the fat accumulation and the underlying mechanism in a mouse model of ACM induced by cardiac-specific knockout of Dsg2 (CS- Dsg2 –/– ). Heart failure and cardiac lipid accumulation were observed in CS- Dsg2 –/– mice. We demonstrated that these phenotypes were caused by decline of fatty acid (FA) β -oxidation resulted from impaired mammalian target of rapamycin (mTOR) signaling. Rapamycin worsened while overexpression of mTOR and 4EBP1 rescued the FA β -oxidation pathway in CS- Dsg2 –/– mice. Reactivation of PPAR α by fenofibrate or AAV9- Pparα significantly alleviated the lipid accumulation and restored cardiac function. Our results suggest that impaired mTOR–4EBP1–PPAR α -dependent FA β -oxidation contributes to myocardial lipid accumulation in ACM and PPAR α may be a potential target for curative treatment of ACM. Deletion of Dsg2 in cardiomyocytes leads to downregulation of the mTOR–4EBP1–PPAR α signaling pathway, resulting in impaired fatty acid β -oxidation pathway and the development of arrhythmogenic cardiomyopathy.
科研通智能强力驱动
Strongly Powered by AbleSci AI